News | February 19, 2025
Merck’s Welireg receives European approval for two indications
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
Expansion makes Merck Life Science in Bengaluru a key manufacturing location in the APAC region
Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535
Merck will record a pre-tax charge relating to the upfront payment of $588 million
Merck has also decided to end the favezelimab clinical development program
Acquisition to advance company's next generation biology portfolio with internationally recognized pioneer in organoid development
An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season
Based on data, 1.75 mg/kg dose established as recommended dose for Phase 3 trial of this investigational antibody-drug conjugate
The initiative will encourage and motivate emerging biotech startups, innovators and entrepreneurs
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
